Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Castle Biosciences (CSTL) Short-Term Debt issuances (2019)

Castle Biosciences' Short-Term Debt issuances history spans 1 years, with the latest figure at $11.7 million for Q1 2019.

On a quarterly basis, Short-Term Debt issuances changed N/A to $11.7 million in Q1 2019 year-over-year; TTM through Dec 2019 was $11.7 million, a N/A change, with the full-year FY2019 number at $11.7 million, changed N/A from a year prior.
Short-Term Debt issuances hit $11.7 million in Q1 2019 for Castle Biosciences.
Over the last five years, Short-Term Debt issuances for CSTL hit a ceiling of $11.7 million in Q1 2019 and a floor of $11.7 million in Q1 2019.